Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Feinberg

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Obstetrics and Gynecology|June 13, 2019
Oral or Vaginal Misoprostol for Labor Induction and Cesarean Delivery RiskRoxane C Handal-Orefice, Alexander M Friedman, Sujata M Chouinard, et al.
Future Oncology (London, England)|January 19, 2026
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapyAmit G Singal, Kirhan Özgürdal, Zdravko Vassilev, et al.
Poultry Science|March 20, 2016
Symposium: Animal welfare challenges for today and tomorrowYvonne Vizzier Thaxton, Karen D Christensen, Joy A Mench, et al.
Future Oncology (London, England)|January 8, 2026
Real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC)Marvin Nguyen, Ruchit Shah, Jon Apple, et al.
Journal of Comparative Effectiveness Research|January 27, 2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisGordon Lam, Hanke Zheng, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|November 18, 2024
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisAlexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, et al.
Clinical Genitourinary Cancer|January 28, 2026
Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?Alicia K Morgans, Maelys Touya, Nader El-Chaar, et al.
JAMA Network Open|May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell CarcinomaNeil J Shah, Yaa Ababio, Anthony Eccleston, et al.
Oncology and Therapy|March 26, 2026
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review StudyBinod Dhakal, Moshe Y Levy, Gilbert Ko, et al.
JAMA Network Open|June 9, 2025
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With NivolumabRegina Barragán-Carrillo, Hedyeh Ebrahimi, William S John, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Obstetrics and Gynecology|June 13, 2019
Oral or Vaginal Misoprostol for Labor Induction and Cesarean Delivery RiskRoxane C Handal-Orefice, Alexander M Friedman, Sujata M Chouinard, et al.
Future Oncology (London, England)|January 19, 2026
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapyAmit G Singal, Kirhan Özgürdal, Zdravko Vassilev, et al.
Poultry Science|March 20, 2016
Symposium: Animal welfare challenges for today and tomorrowYvonne Vizzier Thaxton, Karen D Christensen, Joy A Mench, et al.
Future Oncology (London, England)|January 8, 2026
Real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC)Marvin Nguyen, Ruchit Shah, Jon Apple, et al.
Journal of Comparative Effectiveness Research|January 27, 2026
First-line tumor necrosis factor inhibitor versus abatacept treatment choice in real-world patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisGordon Lam, Hanke Zheng, Andrew Klink, et al.
Journal of Comparative Effectiveness Research|November 18, 2024
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritisAlexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, et al.
Clinical Genitourinary Cancer|January 28, 2026
Does Physician Documentation of Patients' Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?Alicia K Morgans, Maelys Touya, Nader El-Chaar, et al.
JAMA Network Open|May 21, 2026
Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell CarcinomaNeil J Shah, Yaa Ababio, Anthony Eccleston, et al.
Oncology and Therapy|March 26, 2026
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review StudyBinod Dhakal, Moshe Y Levy, Gilbert Ko, et al.
JAMA Network Open|June 9, 2025
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With NivolumabRegina Barragán-Carrillo, Hedyeh Ebrahimi, William S John, et al.
Pageof 5